 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...8788899091929394959697...143144» |
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Wound healing deficits in severe generalized recessive dystrophic epidermolysis bullosa along anticancer treatment with cetuximab. (Pubmed Central) - Feb 25, 2020
No abstract available
- ||| oxaliplatin / Generic mfg., fluorouracil / Generic mfg., Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical: maintenance Cetuximab alone or adding to inf 5FU-FA to this regimen without oxaliplatin-till progression? (Twitter) - Feb 24, 2020
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Reimbursement: how do you even get Cetuximab approved by insurance? (Twitter) - Feb 24, 2020
- || Clinical, Journal: Efficacy of second-line chemotherapy after a first-line triplet in patients with metastatic colorectal cancer. (Pubmed Central) - Feb 24, 2020
Exposing patients with metastatic colorectal cancer (mcrc) to all three active chemotherapeutic agents (oxaliplatin, irinotecan, fluorouracil) has improved survival...Concurrent bevacizumab was given in 16 patients (57%), and cetuximab, in 2 (7%)...Median progression-free survival was 4.8 months (95% ci: 2.4 months to 9.6 months), and overall survival was 15 months (95% ci: 9.6 months to 20.4 months). Second-line chemotherapy after first-line triplet therapy in mcrc is feasible and suggests efficacy comparable to that reported for second-line therapy after a doublet, regardless of the agent used.
- |||| Opdivo (nivolumab) / BMS
New P2 trial, Combination therapy, PD(L)-1 Biomarker, IO biomarker: Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX) (clinicaltrials.gov) - Feb 24, 2020
P2, N=141, Not yet recruiting, Sponsor: Grupo Espa
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Perioperative cetuximab plus chemotherapy reduces overall survival in metastatic disease. (Pubmed Central) - Feb 23, 2020
Second-line chemotherapy after first-line triplet therapy in mcrc is feasible and suggests efficacy comparable to that reported for second-line therapy after a doublet, regardless of the agent used. No abstract available
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Skin toxicity of cetuximab in patients with metastatic colorectal carcinoma (mCRC). (Pubmed Central) - Feb 23, 2020
No abstract available No abstract available
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Clinical, P2 data, Journal: ANCHOR CRC: a phase 2, open-label, single arm, multicenter study of encorafenib (ENCO), binimetinib (BINI), plus cetuximab (CETUX) in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC). (Pubmed Central) - Feb 23, 2020
No abstract available No abstract available
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer: Nordic 8 results. (Pubmed Central) - Feb 23, 2020
No abstract available No abstract available
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Journal, HEOR, Combination therapy: The Velindre cancer centre experience of panitumumab versus cetuximab in combination with chemotherapy for metastatic colorectal cancer: a comparison of toxicity and economic evaluation. (Pubmed Central) - Feb 23, 2020
No abstract available No abstract available
- ||| Clinical, P3 data, Journal: BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer. (Pubmed Central) - Feb 23, 2020
No abstract available No abstract available
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Triplet chemotherapy plus cetuximab as first-line treatment in RAS wild-type metastatic colorectal carcinoma patients. (Pubmed Central) - Feb 23, 2020
No abstract available No abstract available
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, irinotecan / Generic mfg., capecitabine / Generic mfg.
Clinical, Journal: The use of oral capecitabine with irinotecan and cetuximab (mCAPIRI-C) among colorectal cancer patients with unresectable liver-only metastases. (Pubmed Central) - Feb 23, 2020
No abstract available No abstract available
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date: ERM-PT-HNSCC: Early Response Evaluation of Proton Therapy by PET-imaging in Squamous Cell Carcinoma Located in the Head and Neck (clinicaltrials.gov) - Feb 23, 2020
P=N/A, N=40, Not yet recruiting, Sponsor: Leiden University Medical Center
No abstract available Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Metastases: CA225200: PhII ICb With/Without Erbitux in MBC Pts (clinicaltrials.gov) - Feb 23, 2020
P2, N=154, Active, not recruiting, Sponsor: US Oncology Research
Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Dec 2022 --> Dec 2023 Trial completion date: Dec 2019 --> Dec 2020
- || barecetamab (ISU104) / ISU Abxis
Enrollment change, Metastases: Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Feb 23, 2020
P1, N=33, Recruiting, Sponsor: ISU Abxis Co., Ltd.
Trial completion date: Dec 2019 --> Dec 2020 N=55 --> 33
- ||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Long-Term Results of NRG Oncology RTOG 0617: Standard- vs High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III NSCLC https://t.co/bpwWib4qIb (Twitter) - Feb 22, 2020
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Nicholas D. James, PhD, MBBS, on Bladder Cancer: Cetuximab With Chemoradiotherapy https://t.co/QSWagge6FV #GU20 #blcsm #oncology #cancer @ICR_LONDON @Prof_Nick_James (Twitter) - Feb 22, 2020
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, patritumab (U3-1287) / Amgen
Clinical, P1 data, Journal: Patritumab with Cetuximab Plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase-Ib Study. (Pubmed Central) - Feb 22, 2020
N=55 --> 33 Patritumab (18-mg/kg LD, 9-mg/kg MD) plus cetuximab/platinum was tolerable, active in SCCHN, and was selected as the phase II dose-regimen.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, paclitaxel / Generic mfg.
Journal, Combination therapy: Synergistic combination therapy of lung cancer: Cetuximab functionalized nanostructured lipid carriers for the co-delivery of paclitaxel and 5-Demethylnobiletin. (Pubmed Central) - Feb 21, 2020
CET-PTX/DMN-NLCs exhibited the most remarkable in vivo tumor inhibition efficiency, which suspended the tumor growth from 1010.23 to 211.18 mm at the end of the study. The highest tumor accumulation amount and low toxicity made CET-PTX/DMN-NLCs a promising system for the synergistic combination therapy of lung cancer.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Silencing Smad4 attenuates sensitivity of colorectal cancer cells to cetuximab by promoting epithelial‑mesenchymal transition. (Pubmed Central) - Feb 21, 2020
However, Smad4 overexpression enhanced SW480 cell sensitivity to cetuximab. In conclusion, Smad4 may serve a vital role in the sensitivity of CRC cells to chemotherapeutic drugs by promoting EMT.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Non-invasive targeted iontophoretic delivery of cetuximab to skin. (Pubmed Central) - Feb 21, 2020
Therapeutic concentrations of CTX in the viable epidermis, upper dermis and lower dermis were achieved following iontophoresis for 2, 4 and 8 h, respectively. The results demonstrate the topical delivery of a 152 kDa monoclonal antibody into skin in a targeted, controlled and entirely non-invasive manner.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Surgery, Metastases: SWOG S1613: S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Feb 21, 2020
P2, N=130, Recruiting, Sponsor: Southwest Oncology Group
The results demonstrate the topical delivery of a 152 kDa monoclonal antibody into skin in a targeted, controlled and entirely non-invasive manner. Active, not recruiting --> Recruiting
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Retrospective data, Journal, BRCA Biomarker, PARP Biomarker: A Bayesian network meta-analysis of the efficacy of targeted therapies and chemotherapy for treatment of triple-negative breast cancer. (Pubmed Central) - Feb 20, 2020
In conclusion, our results indicated that the addition of bevacizumab to CT was beneficial for TNBC patients, and olaparib had a great effect in PFS and ORR, especially for those with BRCA mutations. When combined with CT, targeted agents including iniparib, sorafenib, cetuximab, and ipatasertib may have better efficacies for treating TNBC.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, doxorubicin hydrochloride / Generic mfg.
Journal: Selective delivery of doxorubicin to EGFR+ cancer cells by Cetuximab-DNA conjugates. (Pubmed Central) - Feb 20, 2020
In vitro cytotoxicity and selectively cancer cell killing was investigated against two EGFR+ cell lines (KB and MDA-MB-231) and one EGFR- cell line (NIH-3T3). Cytotoxicity and flow cytometer data showed that doxorubicin loaded in cetuximab-DNA conjugates were more potent in cell cytotoxicity than free doxorubicin in EGFR overexpressed cell lines, suggesting that they were more selectively and easily taken up within cells followed by rapid release of doxorubicin from the system into the cytoplasm from endosomes.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, capecitabine / Generic mfg.
Clinical, Journal: Long-term disease control in a metastatic squamous cell carcinoma of the oral cavity treated with maintenance metronomic capecitabine. (Pubmed Central) - Feb 20, 2020
Here we describe the case of a 66-year-old man with a metastatic cancer of oral cavity, who had to discontinue maintenance cetuximab and who achieved prolonged disease control with metronomic capecitabine. We suggest that capecitabine could be an effective and safe maintenance option in case of cetuximab intolerance.
- || Piqray (alpelisib) / Novartis, Erbitux (cetuximab) / Eli Lilly, EMD Serono
P1 data, Journal: A Phase Ib Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity-Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma. (Pubmed Central) - Feb 20, 2020
The recommended phase II dose of BYL719 is 250 mg/day in combination with cetuximab and IMRT in patients with locally advanced HNSCC. Further evaluation of the addition of BYL719 to the platinum-sparing regimen of cetuximab and IMRT in the treatment of locally advanced HNSCC is warranted.
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Retrospective data, Review, Journal: Tumor sidedness and efficacy of first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancer: A network meta-analysis. (Pubmed Central) - Feb 19, 2020
Cetuximab, closely followed by panitumumab, is the most effective treatment in left-sided RAS WT mCRC. Bevacizumab is more effective in right-sided mCRC.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Checkpoint inhibition, Metastases: Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure (clinicaltrials.gov) - Feb 19, 2020
P2, N=50, Not yet recruiting, Sponsor: Medical University of Vienna
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Osteopontin Mediates Cetuximab Resistance via the MAPK Pathway in NSCLC Cells. (Pubmed Central) - Feb 19, 2020
These results suggested that OPN promoted malignant progression and mediated drug resistance via the MAPK signaling pathway in NSCLC cells. This study reveals the important role of OPN in NSCLC cells, making it a potential target for improving chemotherapy efficiency in patients with NSCLC.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Retrospective data, Journal: Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study. (Pubmed Central) - Feb 19, 2020
Our study shows that cetuximab is safe and efficient for the treatment of patients, even elderly ones, with advanced cSCC. These results indicate that cetuximab is a promising agent to test in new combinations, especially with immune checkpoint inhibitors such as anti-PD-1 agents.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
meant "worse with cetuximab" .. oops ... (Twitter) - Feb 19, 2020
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
I would take these plots with a grain of salt and a bit of sugar on top ... Every subgroup did worse without cetuximab as you would expect -- except 3 with wide CIs (so add another grain of salt)... One of them is the RAS/RAF mutated group that seem to favor cetuximab ! (Twitter) - Feb 19, 2020
- Encorafenib plus Cetuximab With or Without Binimetinib for BRAF V600E–Mutant Metastatic Colorectal Cancer: Management of Adverse Events from a Randomized, 3-Arm, Phase 3 Study vs. the Choice of Either Irinotecan or FOLFIRI plus Cetuximab (BEACON CRC) (Henry B. Gonzalez Convention Center - Tower View Registration) - Feb 17, 2020 - Abstract #ONS2020ONS_511;
P3
Innovation: AEs that occurred during the BEACON CRC study on the experimental arms were generally manageable, reversible, and infrequently associated with treatment discontinuation. Clinical Trial ID: NCT02928224
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Sphenoid Sinus Basaloid Squamous Cell Carcinoma In An Asymptomatic Adult Male: Case Report With Review Of The Literature (Henry B. Gonzalez Convention Center - Tower View Registration) - Feb 17, 2020 - Abstract #ONS2020ONS_431;
Post-operatively, the patient received a course of radiation and chemotherapy, followed by target therapy with Cetuximab (Erbitux ®) plus regular follow-ups...To the best of our knowledge, only one case of sphenoid sinus BSCC was ever reported. Therefore, we are reporting this case for its rarity.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open: Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma (clinicaltrials.gov) - Feb 17, 2020
P2, N=70, Recruiting, Sponsor: Jonsson Comprehensive Cancer Center
Therefore, we are reporting this case for its rarity. Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Preclinical, Journal, Combination therapy: In vitro elimination of EGFR-overexpressing cancer cells by CD32A chimeric receptor T cells in combination with cetuximab or panitumumab. (Pubmed Central) - Feb 15, 2020
The ADCC of Fcγ-CR T cells was associated with the over-expression of EGFR on ECCs. In conclusion, CD32A -CR T cells are efficiently redirected by cetuximab or panitumumab against BC cells overexpressing EGFR.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy. (Pubmed Central) - Feb 15, 2020
Neoadjuvant chemoradiation increased the percentage of sarcopenia. Sarcopenic patients are at higher risk for increased toxicity during neoadjuvant radiochemotherapy and showed a non-significant trend to more postoperative morbidity.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: EGFR-Specific Tyrosine Kinase Inhibitor Modifies NK Cell-Mediated Antitumoral Activity against Ovarian Cancer Cells. (Pubmed Central) - Feb 15, 2020
We studied treatment-related structural and functional changes on tumor and immune cells in the presence of the anti-EGFR antibody cetuximab and investigated NK-mediated antitumoral activity...Our data suggest that sensitization of tumor cells by anti-EGFR TKIs differentially modulates interactions with NK cells. These data have important implications for the design of chemo-immuno combination therapies in this tumor entity.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
P1/2 data, Journal: The Phase I/II ACCEPT Trial: Concurrent Cetuximab and Intensity-Modulated Radiotherapy with Carbon Ion Boost for Adenoid Cystic Carcinoma of the Head and Neck: Cetuximab and IMRT/Carbon Ions for ACC. (Pubmed Central) - Feb 15, 2020
P1/2
Outcomes of this trial were satisfactory. Although the trial did not meet the pre-defined criteria of feasibility, owing to the comparatively high rates of grade 3 dermatitis, the latter are numerically comparable to existing cetuximab+RT data.
- | fluorouracil / Generic mfg., Erbitux (cetuximab) / Eli Lilly, EMD Serono, GC-1118A / Green Cross
Journal: GC1118, a novel anti-EGFR antibody, has potent KRAS mutation-independent antitumor activity compared with cetuximab in gastric cancer. (Pubmed Central) - Feb 14, 2020
Taken together, GC1118 alone or in combination with cytotoxic chemotherapeutic agents exerted more potent anti-tumor effects than cetuximab in GC cells, regardless of KRAS status. These findings support the further clinical development of GC1118 for the treatment of GC.
- ||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Even I thought -Targetting the pathway downstream, do u need to separately block the EGFR? The rationale of comibining a EGFRi in BEACON study with (cetuximab/Binimetinib/Encorafenib in BRAFmutant mCRC )- was that BRAF inhibition causes rapid feedback activation thru the EGFR (Twitter) - Feb 14, 2020
- ||||| fluorouracil / Generic mfg., Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical: Second poster - outcomes in the TUXEDO trial adding cetuximab to RT/MMC/5FU in MIBC. 95% pts free from MIBC recurrence at 2 years. QOL data excellent #gu20 (Twitter) - Feb 14, 2020
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal, Adverse events: Blepharitis: a rare side effect related to cetuximab in patient with colorectal cancer. (Pubmed Central) - Feb 14, 2020
These findings support the further clinical development of GC1118 for the treatment of GC. No abstract available
- || Clinical, Review, Journal: Adjuvant chemotherapy in resected colon cancer: When, how and how long? (Pubmed Central) - Feb 14, 2020
Only oxaliplatin added to fluorouracil/capecitabine has been shown to be superior beyond a fluropyrimidine alone in the adjuvant setting...In the era of cancer gene expression-based subtyping, the Colorectal Cancer Subtyping Consortium has proposed a four-subgroup molecular classification system for colorectal cancer, consisting of CMS1 (immune), CMS2 (canonical), CMS3 (metabolic) and CMS4 (mesenchymal). In this review, we present and analyze the available data on efficacy and toxicity of the combination regimen approved for treatment of resected colon cancer, and discuss the questions of when, how and how long we need to treat such patients.
- || cisplatin / Generic mfg., Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Review, Journal: Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Unsuitable to Receive Cisplatin-Based Therapy. (Pubmed Central) - Feb 13, 2020
Patients with any pre-existing comorbidities that may be exacerbated by high-dose cisplatin treatment can be redirected to a non-cisplatin-based option to minimize the risk of treatment non-adherence. High-dose cisplatin plus radiotherapy remains the preferred treatment for fit patients with unresected LA SCCHN; patients who are unsuitable or borderline unsuitable for high-dose cisplatin could be identified using available tests for potential comorbidities and should be offered alternative treatments, such as cetuximab plus radiotherapy.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal: Cancer Cells Expressing Oncogenic Rat Sarcoma Show Drug-Addiction Toward Epidermal Growth Factor Receptor Antibodies Mediated by Sustained MAPK Signaling. (Pubmed Central) - Feb 13, 2020
Our data suggests that EGFR antibodies paradoxically sustain MAPK signaling downstream of oncogenic RAS thereby driving proliferation of RAS mutant tumors or tumor subclones. The observed drug-addiction encourages fixed-duration or liquid-biopsy-guided drug holiday concepts to preventively clear RAS mutant subclones selected under EGFR-directed therapeutic pressure.
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical: This week @marshalj23 also highlighted "Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: longterm results of a multicentre, randomised, controlled, phase 3 trial" @TheLancetOncol as interesting. Via: https://t.co/P2T6CiTvcR. (Twitter) - Feb 13, 2020
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Nanoparticle encapsulated TLR7/8 agonists activate both innate and adaptive immune responses (204B, Pennsylvania Convention Center) - Feb 13, 2020 - Abstract #ACSSp2020ACS_Sp_10555;
TLR7/8 agonist-loaded NP treatment significantly enhanced the anti-tumor efficacy of cetuximab and an anti-HER2/neu antibody in mouse tumor models. Our results suggest that acidic-pH responsive polymeric nanoparticles are an efficient TLR7/8 agonist delivery platform for cancer immunotherapy.
- Orencia (abatacept) / BMS, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Fast dynamic surfactant reduces aggregation of biologics (Freedom Ballroom E/F, Philadelphia 201 Hotel) - Feb 13, 2020 - Abstract #ACSSp2020ACS_Sp_7983;
FM1000 also reduced subvisible particle formation in a cetuximab model formulation. Coupling aggregation performance with fundamental surfactant interfacial dynamics and behavior will help better understand the underlying mechanisms of protein (de)stabilization, enabling the development of higher stability formulations.